+

WO2010117992A3 - Identification et traitement d'un cancer - Google Patents

Identification et traitement d'un cancer Download PDF

Info

Publication number
WO2010117992A3
WO2010117992A3 PCT/US2010/030054 US2010030054W WO2010117992A3 WO 2010117992 A3 WO2010117992 A3 WO 2010117992A3 US 2010030054 W US2010030054 W US 2010030054W WO 2010117992 A3 WO2010117992 A3 WO 2010117992A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
coupled identification
gallium
identification
Prior art date
Application number
PCT/US2010/030054
Other languages
English (en)
Other versions
WO2010117992A2 (fr
Inventor
Lawrence Bernstein
Original Assignee
Lawrence Bernstein
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lawrence Bernstein filed Critical Lawrence Bernstein
Priority to EP10762289A priority Critical patent/EP2416788A4/fr
Priority to US13/256,118 priority patent/US20110318265A1/en
Publication of WO2010117992A2 publication Critical patent/WO2010117992A2/fr
Publication of WO2010117992A3 publication Critical patent/WO2010117992A3/fr
Priority to US14/095,066 priority patent/US20140093451A1/en
Priority to US14/457,920 priority patent/US20140363374A1/en
Priority to US15/791,984 priority patent/US20180036439A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0472—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention concerne des méthodes de traitement anticancéreux, lesdites méthodes consistant à identifier un patient atteint d'un cancer avide de gallium en utilisant un scanner au gallium ou d'autres moyens, et à traiter ledit patient avec une composition à base de gallium pharmaceutiquement acceptable.
PCT/US2010/030054 2009-04-07 2010-04-06 Identification et traitement d'un cancer WO2010117992A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP10762289A EP2416788A4 (fr) 2009-04-07 2010-04-06 Identification et traitement d'un cancer
US13/256,118 US20110318265A1 (en) 2009-04-07 2010-04-06 Coupled identification and treatment of cancer
US14/095,066 US20140093451A1 (en) 2009-04-07 2013-12-03 Coupled identification and treatment of cancer
US14/457,920 US20140363374A1 (en) 2009-04-07 2014-08-12 Coupled identification and treatment of cancer
US15/791,984 US20180036439A1 (en) 2009-04-07 2017-10-24 Coupled identification and treatment of cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16728209P 2009-04-07 2009-04-07
US61/167,282 2009-04-07

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/256,118 A-371-Of-International US20110318265A1 (en) 2009-04-07 2010-04-06 Coupled identification and treatment of cancer
US14/095,066 Continuation US20140093451A1 (en) 2009-04-07 2013-12-03 Coupled identification and treatment of cancer

Publications (2)

Publication Number Publication Date
WO2010117992A2 WO2010117992A2 (fr) 2010-10-14
WO2010117992A3 true WO2010117992A3 (fr) 2011-02-24

Family

ID=42936842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/030054 WO2010117992A2 (fr) 2009-04-07 2010-04-06 Identification et traitement d'un cancer

Country Status (3)

Country Link
US (4) US20110318265A1 (fr)
EP (1) EP2416788A4 (fr)
WO (1) WO2010117992A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058210A2 (fr) 2006-11-09 2008-05-15 Bernstein Lawrence R Administration locale de compositions de gallium pour traiter la douleur
JP2012522789A (ja) 2009-03-30 2012-09-27 ニッキ ファーマ インク． 骨粗鬆症の治療法
JP2013521229A (ja) * 2010-02-26 2013-06-10 ニッキ ファーマ インク． 脳腫瘍を処置するための方法
EP2560648A4 (fr) * 2010-04-23 2013-10-02 Niiki Pharma Inc Méthode de traitement du cancer du pancréas

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059397A2 (fr) * 2001-12-26 2003-07-24 Immunomedics, Inc. Marquage d'agents de ciblage au gallium-68 et au gallium-67
WO2007055885A2 (fr) * 2005-11-04 2007-05-18 Genta Incorporated Compositions pharmaceutiques de gallium et procedes
JP2008526772A (ja) * 2004-12-29 2008-07-24 エミスフェアー・テクノロジーズ・インク ガリウム塩の製剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999051277A1 (fr) * 1998-04-08 1999-10-14 Oregon Health Sciences University Activation de la fixation cellulaire de gallium
WO2006024026A2 (fr) * 2004-08-25 2006-03-02 The Board Of Trustees Of The Leland Stanford Junior University Profil moleculaire des cancers reagissant favorablement a la statine et utilisations
EP1945272B1 (fr) * 2005-11-01 2013-09-11 Novartis AG Méthode de scintigraphie
US20070231407A1 (en) * 2006-04-04 2007-10-04 Chitambar Christopher R Method of treating gallium-nitrate resistant tumors using gallium-containing compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059397A2 (fr) * 2001-12-26 2003-07-24 Immunomedics, Inc. Marquage d'agents de ciblage au gallium-68 et au gallium-67
JP2008526772A (ja) * 2004-12-29 2008-07-24 エミスフェアー・テクノロジーズ・インク ガリウム塩の製剤
WO2007055885A2 (fr) * 2005-11-04 2007-05-18 Genta Incorporated Compositions pharmaceutiques de gallium et procedes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PHILIPPE COLLERYA ET AL.: "Gallium in cancer treatment.", CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY., vol. 42, no. ISS.3, June 2002 (2002-06-01), pages 283 - 296 *

Also Published As

Publication number Publication date
EP2416788A4 (fr) 2012-08-22
US20110318265A1 (en) 2011-12-29
WO2010117992A2 (fr) 2010-10-14
US20180036439A1 (en) 2018-02-08
US20140093451A1 (en) 2014-04-03
EP2416788A2 (fr) 2012-02-15
US20140363374A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
WO2010097788A3 (fr) Agents thérapeutiques de visfatine pour traiter l'acné et d'autres conditions
MX363243B (es) Composiciones para tratar cáncer y usos de dichas composiciones.
WO2011005493A3 (fr) Procédés et matériels pour réparation de tissu
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
MX2012000034A (es) Metodos para el tratamiento o la prevencion de la fatiga.
WO2009114703A3 (fr) Thérapie combinée pour le traitement d'un cancer
IL215061A0 (en) Compounds, compositions and methods of treating cancer and fibrotic diseases
WO2009151907A3 (fr) Compositions et procédés permettant d'utiliser des cellules pour traiter le tissu cardiaque
WO2010132622A3 (fr) Conjugués anti-cd20-cpg et méthodes de traitement des lymphomes b
WO2011020107A3 (fr) Compositions et méthodes de dépistage et de traitement du cancer du sein
GB2499559A (en) Treating cough and tussive attacks
PH12013500411A1 (en) Treatment of myocardial infarction using tgf - beta antagonists
WO2010088450A3 (fr) Procédés de traitement de maladies associées à la modulation de serca
MX2009007247A (es) Metodo para el tratamiento de afecciones asociadas con actividad aumentada de 5-lipoxigenasa y/o leucotrienos.
WO2011044523A3 (fr) Compositions et procédés destinés à traiter l'obésité
MX344281B (es) Uso de paulownin y/o extractos de madera de paulownia para preparar composiciones topicas para el tratamiento de la celulitis.
WO2010117992A3 (fr) Identification et traitement d'un cancer
MX2010012454A (es) Metodo para promover la curacion de heridas.
WO2013055889A3 (fr) Échafaudages implantables et leurs procédés d'utilisation
WO2012016229A3 (fr) Traitement à l'ocytocine visant à améliorer la mémoire et abaisser le taux de glucose dans le sang
WO2011091154A3 (fr) Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
WO2012037008A3 (fr) Traitement thérapeutique de la leucémie à réarrangement de mll
AU2010298020A8 (en) Combination
WO2010149357A3 (fr) Méthodes de traitement du cancer utilisant la corticolibérine (crf)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10762289

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 13256118

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2010762289

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载